[Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives]

Dtsch Med Wochenschr. 2005 Jun 10;130(23):1438-42. doi: 10.1055/s-2005-870836.
[Article in German]
No abstract available

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Bevacizumab
  • Cetuximab
  • ErbB Receptors / antagonists & inhibitors
  • Erlotinib Hydrochloride
  • Gefitinib
  • Genes, abl / drug effects
  • Humans
  • Imatinib Mesylate
  • Neoplasms / drug therapy*
  • Patient Selection
  • Piperazines / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Pyrimidines / therapeutic use
  • Quinazolines / therapeutic use
  • Trastuzumab
  • Vascular Endothelial Growth Factor A / immunology

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Quinazolines
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Imatinib Mesylate
  • Erlotinib Hydrochloride
  • ErbB Receptors
  • Protein-Tyrosine Kinases
  • Trastuzumab
  • Cetuximab
  • Gefitinib